AOP Health’s Rapiblyk (landiolol) Receives the US FDA’s Approval for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting 

Shots:   

• The US FDA has granted approval to Rapiblyk for treating severe heart condition supraventricular tachycardia (atrial fibrillation and atrial flutter) in critical care setting 

• Approval was supported by 5 clinical trials assessing the safety & efficacy of Rapiblyk (9.3 to 74.6 mcg/kg/min) vs PBO in adults (n=317) with supraventricular tachycardia, showing 40-90% vs 0-11% reduction in the heart rate & 9.9% vs 1% AEs 

• Rapiblyk, adrenergic receptor antagonist with beta 1/2 selectivity, lowers heart rate without affecting blood pressure. It is approved in the EU for treating supraventricular tachycardia, incl. atrial fibrillation & flutter, and managing non-compensatory sinus tachycardia 

Ref: AOP Health | Image: AOP Health| Press Release

Related News:- Jazz Pharmaceuticals’ Ziihera (Zanidatamab-hrii) Secures the US FDA’s Accelerated Approval to Treat HER2-Positive (IHC 3+) Biliary Tract Cancer (BTC) 

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com